Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pharmaceutical Industry Careers

AstraZeneca AZ

AstraZeneca’s Lupus treatment misses mark in trial

Anifrolumab failed to show statistically significant reduction in disease activity

AstraZeneca AZ

AZ rival to GSK’s COPD drug Anoro fails head-to-head test

Its combo missed two of the main endpoints of the study

AstraZeneca AZ

AZ’s soon-to-be lung cancer blockbuster Tagrisso approved in Japan

Japanese regulator clears the drug for first-line use in NSCLC

AstraZeneca AZ

New cancer drugs can’t quite plug the revenue hole at AZ

Overall sales fell 5% to $10.33bn

- PMLiVE

AZ’s Lynparza closes in on first line ovarian cancer use

Aims for first-line indication in the ovarian cancer setting

- PMLiVE

Rosalind Franklin Institute invests £6m in disruptive technologies

Will open new AI-enabled research facility based in the UK

- PMLiVE

NICE backs Tesaro’s Zejula via the CDF

Recommends the drug for second-line use in ovarian cancer patients

AstraZeneca AZ

PMCPA takes AZ to task over asthma drug press release

Concluded that the data in the release had not been “placed in context”

AstraZeneca AZ

AZ gets US approval for Veltassa rival Lokelma

But GlobalData predicts Veltassa has the edge due to positive data in chronic hyperkalaemia

- PMLiVE

AstraZeneca and Emulate advance ‘organs-on-chips’ research partnership

Company advances partnership, aiming to integrate technology into full-scale R&D efforts

- PMLiVE

CHMP backs first-line use for AZ’s Tagrisso in lung cancer

AstraZeneca, Roche and Gilead among companies one step closer to approval

AstraZeneca AZ

AZ’s immuno-oncology combo fails another lung cancer trial

Latest failure casts doubt on company’s CTLA4 drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links